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Novelty and Impact: Fetuin-A is a liver protein known to induce insulin resistance.  
Hyperinsulinemia is a possible risk factor for colorectal cancer, but whether fetuin-A plays a role  
in the etiology of colorectal cancer is currently unclear. In this prospective study, we found a  
modest linear association between fetuin-A and higher risk of colorectal cancer, but genetically  
raised fetuin-A was unrelated to colorectal cancer risk, arguing against a direct role of fetuin-A in  
colorectal carcinogenesis.   
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Abstract  
Fetuin-A, also referred to as α2-Heremans-Schmid glycoprotein (AHSG) is a liver protein known  
to inhibit insulin actions. Hyperinsulinemia is a possible risk factor for colorectal cancer,  
however, the role of fetuin-A in the development of colorectal cancer is unclear. We investigated  
the association between circulating fetuin-A and colorectal cancer risk in a nested case-control  
study within the European Prospective Investigation into Cancer and Nutrition. Fetuin-A  
concentrations were measured in pre-diagnostic plasma samples from 1,367 colorectal cancer  
cases and 1,367 matched controls. In conditional logistic regression models adjusted for potential  
confounders the estimated relative risk (95% CI) of colorectal cancer per 40 µg/mL higher fetuin- 
A concentrations (approximately one standard deviation) was 1.13 (1.02, 1.24) overall, 1.21  
(1.05, 1.39) in men and 1.06 (0.93, 1.22) in women, 1.13 (1.00, 1.27) for colon cancer and 1.12  
(0.94, 1.32) for rectal cancer. To improve causal inference in a Mendelian Randomization  
approach, 5 tagging single nucleotide polymorphisms of the AHSG gene were genotyped in a  
subset of 456 case-control pairs. The AHSG allele-score explained 21% of the inter-individual  
variation in plasma fetuin-A concentrations. In instrumental variable analysis, genetically raised  
fetuin-A was not associated with colorectal cancer risk (relative risk per 40 µg/mL genetically  
determined higher fetuin-A was 0.98, 95% CI 0.73, 1.33). The findings of our study indicate a  
modest linear association between fetuin-A concentrations and risk of colorectal cancer, but  
suggest that fetuin-A may not be causally related to colorectal cancer development.   
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Introduction  
Fetuin-A, also referred to as α2-Heremans-Schmid glycoprotein (AHSG), is a protein that is  
almost exclusively expressed and secreted by the liver, particularly in nonalcoholic fatty liver  
disease (NAFLD) 
1
. Fetuin-A plays a role in the insulin signaling pathway, acting as an inhibitor  
of insulin receptor tyrosine kinase 
2
. Mice deficient for the AHSG gene displayed improved  
insulin sensitivity, lower body weight and were resistant to weight gain upon a high-fat diet 
3, 4
.  
Further experimental studies in rodents have shown that fetuin-A induces insulin resistance 
5
.  
These findings are supported by a number of human studies that observed positive associations  
between circulating fetuin-A and measures of insulin resistance 
1, 6, 7
. In addition, a bidirectional  
Mendelian Randomization study suggested a causal relationship between fetuin-A and body mass  
index
8
. Recently, positive associations between fetuin-A concentrations and risk of type 2  
diabetes 
9-11
 and cardiovascular disease 
12, 13
 have been observed in large prospective studies.  
Insulin resistance and associated metabolic states such as hyperinsulinemia, hyperglycemia, low- 
grade inflammation and hypoadiponectinemia have been associated with increased risk of  
colorectal cancer in several prospective studies 
14
 including the European Prospective  
Investigation into Cancer and Nutrition (EPIC) 
15-18
. However, it is currently unknown whether  
fetuin-A plays a role in the development of colorectal cancer. Therefore, we aimed to investigate  
the association between circulating fetuin-A and risk of colorectal cancer in a prospective nested  
case-control study in EPIC. Because observational studies relating circulating biomarker  
concentrations to risk of disease may be affected by residual confounding and reverse causation,  
even in a prospective study design, we additionally aimed to examine potential causality by using  
single nucleotide polymorphisms (SNPs) in the AHSG gene as relatively unbiased proxies for  
fetuin-A concentration using a Mendelian Randomization approach 
19
.   
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Material and Methods  
Study population  
The EPIC study is an ongoing cohort study with over 520,000 participants from 23 centers in 10  
Western European countries who were between 25 and 70 years old at study recruitment in the  
period between 1992 and 2000. Details on the methods of the EPIC study design were reported  
previously 
20
. Briefly, standardized lifestyle and personal history questionnaires, anthropometric  
data and blood samples were collected from most participants at recruitment, prior to disease  
onset or diagnosis.  Diet over the previous 12 months was assessed at recruitment by validated  
country-specific questionnaires.  The EPIC study was approved by the ethics review board of the  
International Agency for Research on Cancer (IARC, Lyon, France) and the local review boards  
of the participating institutions.  
  
Identification of colorectal cancer cases  
Incident cancer cases were identified through record linkage with regional cancer registries in  
most participating countries (Denmark, Norway, the Netherlands, Spain, Sweden, UK and most  
of the Italian study centers). In France, Germany, Greece and Naples (Italy), follow-up was  
performed actively by the participants or their next of kin through mailed questionnaires. Self- 
reported cancer cases were then verified by study physicians using health insurance data,  
information from cancer and clinical registries, and medical records provided by treating  
physicians. The closure dates, which were defined as the latest date of complete follow-up for  
both cancer incidence and vital status, ranged from December 2002 to June 2005. Based on the  
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International Statistical Classification of Diseases, Injury and Causes of Death (10th Revision), 
colorectal cancer was defined as a combination of tumors of the colon (C18.0-C18.7), tumors that 
were overlapping or unspecified (C18.8-C18.9), and tumors of the rectum (C19-C20). 
Nested case-control study 
A total of 1,367 first incident colorectal cancer cases with available questionnaire data and blood 
samples were included in the study. For each case one control was selected using an incidence 
density sampling approach from all cohort members who were alive and free of cancer at the time 
of diagnosis of the index case. Matching factors included sex, age at blood collection (2-months 
to 4-year intervals), study center, time of blood collection (±4 hours) and fasting status (<3, 3-6, 
or >6 hours). Women were additionally matched on menopausal status (premenopausal, 
perimenopausal, postmenopausal, or surgically menopausal). Premenopausal women were 
matched on phase of the menstrual cycle at blood collection (early follicular, late follicular, 
ovulatory, early luteal, mid-luteal, or late luteal), and postmenopausal women were matched on 
current use of hormone replacement therapy (yes/no). Of note, not all matching factors (e.g. 
menstrual cycle) were relevant for the present study, since the case-control set was designed to be 
used for several biomarker studies. 
DNA was available for 1,110 participants (627 colorectal cancer cases, 483 control participants, 
456 case-control pairs), largely due to unavailability of DNA samples from the Danish EPIC 
centers (due to local technical and organizational circumstances that delayed sample retrieval ) 
and a proportion of empty DNA tubes throughout all study centers. Comparison of baseline 
characteristics of control participants with DNA (n=483) with control participants excluded from 
the genetic analyses in this study due to unavailable DNA (n=970) revealed that both groups 
were similar with regards to gender, age, education, and body fatness. 
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Laboratory measurements  
At baseline, blood samples were collected from participants using a standardized protocol and  
stored at the International Agency for Research on Cancer (Lyon, France) in liquid nitrogen at - 
196°C, with the exception of the Danish samples, which were stored in nitrogen vapor at −150°C,  
and Swedish samples, which were stored in -80°C freezers 
20
. Plasma concentrations of fetuin-A  
were measured by enzyme linked immunosorbent assays (BioVendor Human Fetuin-A ELISA)  
in the laboratory of Prof. Pischon, Molecular Epidemiology Group, Max Delbrück Center for  
Molecular Medicine (MDC), Berlin-Buch, Germany. Based on quality control samples (n=40),  
inter-assay coefficient of variation was 8.1%.  
Five tagging single nucleotide polymorphisms (SNPs) in the AHSG gene (rs2248690, rs2070633,  
rs2070635, rs4917 and rs6787344) were selected via HapMap applying stringent criteria (minor  
allele frequency >5% and pairwise r
2
≥0.80), and genotyped using TaqMan methodology.  
Genotype call rates were >99.2% for all assays.  
Circulating concentrations of C-peptide, HbA1c, insulin-like growth factor 1 (IGF-1), total  
cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), low density lipoprotein  
cholesterol (LDL-C),  adiponectin, leptin, and soluble leptin receptor (sOB-R), were also  
available and methods for their measurement are described elsewhere 
15, 17, 18, 21, 22
.   
  
Statistical analysis  
Baseline characteristics between cases and controls were compared using paired t-test, Wilcoxon  
signed rank test, or Mc Nemar’s test. Spearman partial correlation coefficients, adjusted for age  
and sex, were calculated in control participants to examine the relationship between fetuin-A and  
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age (sex-adjusted only), body mass index, waist circumference, physical activity, alcohol intake  
and metabolic biomarkers.  
The association between circulating fetuin-A and risk of colorectal (overall, and separately by  
sex), colon or rectal cancer was evaluated using conditional logistic regression analysis  
calculating odds ratios (ORs) and 95% confidence intervals (95% CI). Because of the incidence  
density sampling, ORs approximate incidence rate ratios which can be interpreted as relative  
risks. Data were analyzed by quintiles of fetuin-A concentrations with cut-offs based on the  
distribution among control participants. Test for trend across quintiles was performed by entering  
the quintile medians as continuous variable to the conditional logistic regression model and  
evaluating its significance by using the Wald-test. We also examined fetuin-A as a continuous  
variable by increments of 40 µg/mL (approximately one standard deviation in fetuin-A  
concentration). We tested for potential non-linear associations between fetuin-A and risk of  
colorectal cancer using fractional polynomials 
23
. ORs were evaluated in a crude model  
conditioned on matching factors only as well as in a multivariable model with adjustment for  
potentially confounding factors including education, Cambridge physical activity index 
24
,  
smoking status, alcohol intake, total energy intake, fiber intake, fruit and vegetable intake, red  
meat intake, processed meat intake and fish and shellfish intake (model 1). Because risk estimates  
from crude models did not differ appreciably from multivariable models, only multivariable  
estimates were presented. In a separate model, we added  body mass index (BMI) and residuals  
of BMI-adjusted waist circumference (to avoid multicollinearity) as covariables (model 2) to  
examine whether adjustment for body fatness changed risk estimates. There were 128 participants  
with missing values on waist circumference in whom the waist circumference residuals were  
substituted with sex-specific median values. In addition, in four participants who had no  
information on dietary intake, sex-specific median dietary intake values were imputed for  
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analysis. Potential heterogeneity in the associations between fetuin-A and colon versus rectal 
cancer was determined using competing risk analysis 
25
. Heterogeneity by sex was evaluated 
using the Q-statistic from the inverse variance method 
26
. 
Additional analyses were performed with exclusion of cases (and their matched controls) 
diagnosed within 2 years after recruitment (n=217 cases, 16% of all cases) to evaluate whether 
our findings may be influenced by reverse causation due to preclinical disease.  
Furthermore, we additionally adjusted for metabolic biomarkers which were significantly 
correlated with fetuin-A and have been shown to be independent risk factors for colorectal cancer 
in previous studies in EPIC 
17, 18, 22
,  including C-peptide, HbA1c, and sOB-R. In order to 
examine C-peptide and HbA1c simultaneously, we added a factor score resulting from factor 
analysis on both variables to the model 
27
. A dataset containing observations with available data 
on all these biomarkers was created, which included 465 case-control pairs (the lower number is 
because HbA1c and C-peptide were assayed only for part of the dataset).  
We also conducted analyses stratified by median age (</≥ 59 years), categories of BMI (<25, 25-
30, ≥30 kg/m
2
), waist circumference (<88 cm in women or <102 cm in men versus ≥88 cm in 
women or ≥102 cm in men),  HbA1c (<5.7%, ≥5.7%), C-peptide (<4.5 ng/mL in men or <3.4 
ng/mL in women versus ≥4.5 ng/mL in men or ≥3.4 ng/mL in women) and tertiles of sex-specific 
alcohol intake. Because numbers of case-control pairs were small in certain strata, stratified 
analyses were conducted using unconditional logistic regression models, adjusting for matching 
variables and all potential covariables included in model 2 (excluding the stratifying variable). 
Potential effect modification (statistical interaction on the multiplicative scale) was evaluated by 
including a product term of stratifying factors (median values of categories) and fetuin-A 
(continuously) in the model and evaluating its statistical significance using Wald’s test. 
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For the Mendelian Randomization (MR) evaluation of the association between genetically raised 
fetuin-A and risk of colorectal cancer, we first examined whether selected SNPs were useful as 
instrumental variables, i.e. predicted fetuin-A concentrations. For this purpose, the association 
between SNPs and fetuin-A was estimated  using univariate linear regression models with robust 
variance 
28
 in control participants. Mean fetuin-A concentrations and 95% confidence intervals 
(95% CI) by genotype and the estimated difference in fetuin-A per minor allele (with genotypes 
coded 0, 1 or 2 according to the number of minor alleles) were calculated. We created a weighted 
allele-score by summing each genotype of the AHSG SNPs that were individually associated with 
higher fetuin-A concentrations 
29, 30
 multiplied by its estimated coefficient from the linear 
regression, and then divided by the sum of weights. To examine whether the AHSG-score was 
independent of potentially confounding factors, we compared the baseline characteristics across 
tertiles of the AHSG-score. The Mendelian Randomization estimate for the association between 
genetically raised fetuin-A and colorectal cancer risk was quantified by instrumental variable 
analysis using two-stage least squares regression. The first stage comprised the linear regression 
of fetuin-A concentrations on the allele score, resulting in predicted values of fetuin-A 
concentrations. The second stage comprised a logistic regression of colorectal cancer on the 
predicted fetuin-A concentrations. Instrument strength for MR analysis was evaluated using the 
F-statistic 
31, 32
 from the first stage regression. Because according to the Mendelian 
Randomization concept AHSG genetic variants can be used as unbiased proxies for fetuin-A 
concentrations
19
, the instrumental variable analyses were conducted without adjustment for 
potential confounders. However, in sensitivity analyses we additionally adjusted for matching 
factors and BMI. 
All reported p-values are two-sided. Instrumental variable analyses were performed using the 
STATA SE 12 (StataCorp, College Station, Texas, USA). All other analyses were performed 
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using SAS Version 4.3- Graphical Software Interface - SAS Enterprise Guide (SAS Institute Inc., 
Cary, North Carolina, USA). 
 
Results 
Incident colorectal cancer cases had at baseline a higher BMI and a higher waist circumference 
and were more often physically inactive than matched control participants (Table 1). Dietary 
intake of fiber was lower in colorectal cancer cases than in control participants. Median pre-
diagnostic blood concentrations of fetuin-A were 227.7 µg/mL in colorectal cancer cases and 
225.1 µ/mL in matched control participants. Compared with their matched controls, colorectal 
cancer cases had higher pre-diagnostic blood concentrations of C-reactive protein, and lower 
concentrations of HDL cholesterol, adiponectin and sOB-R.  
In control participants, plasma fetuin-A was significantly, albeit weakly, positively correlated 
with BMI (r=0.14, p-value <0.0001) and waist circumference (r=0.16, p-value <0.0001), and 
inversely correlated with age (r=-0.07, p-value 0.01) and alcohol consumption (-0.09, p-value 
0.001). Of the metabolic biomarkers, C-peptide (r=0.08, p-value 0.05), HbA1c (r=0.12, p-value 
0.01) and triglycerides (r=0.09, p-value 0.02) were weakly positively correlated with fetuin-A, 
and sOB-R (r=-0.09, p-value 0.02) was inversely correlated with fetuin-A (supplemental table 1). 
C-reactive protein, IGF-1, total cholesterol, adiponectin, and leptin were not significantly 
correlated with fetuin-A (all p-values >0.09). 
Each 40 µg/mL fetuin-A increment (approximately one standard deviation) was significantly 
associated with a 13% higher risk of colorectal cancer (OR 1.13, 95% CI 1.02, 1.24) before, and a 
11% higher risk of colorectal cancer (OR 1.11, 95% CI 1.01, 1.22) after adjustment for body 
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fatness (Table 2). No such association was seen when comparing the highest with the lowest 
quintile. Using fractional polynomials with between one and two degrees, we found no evidence 
that a non-linear function was statistically superior to the linear model (all p-values for non-
linearity >0.10). In analyses by sex, plasma fetuin-A concentrations were significantly positively 
associated with colorectal cancer risk in men both in continuous and categorical analyses (Table 
3). In contrast, no association was observed in women. However, we did not observe statistically 
significant heterogeneity between men and women (p-heterogeneity 0.21 in model 1 and 0.24 in 
model 2). After exclusion of the first two years of follow-up, the positive association between 
plasma fetuin-A and risk of colorectal cancer was slightly attenuated overall, but became slightly 
stronger in men (table 2). When performing analyses according to tumor location, a significant 
positive association between plasma fetuin-A and risk of colon cancer was observed in the 
multivariable model with fetuin-A as a continuous variable (OR per 40 µg/mL 1.13, 95% CI 
1.00, 1.27), but associations were non-significant after adjustment for body fatness (OR 1.11, 
95% CI 0.99, 1.25) (table 3). Comparing the highest with the lowest fetuin-A quintile, a non-
significantly higher risk of colon cancer was observed. Non-significant positive associations 
between plasma fetuin-A and risk of rectal cancer were observed with both continuous and 
categorical analyses. Competing risk analysis revealed no significant differences in the 
associations between fetuin-A and colon versus rectal cancer (p-heterogeneity 0.08 in model 1 
and 0.89 in model 2). After exclusion of the first two years of follow-up, the positive association 
between plasma fetuin-A and risk of colon cancer was attenuated, whereas the positive 
association between fetuin-A and risk of rectal cancer was slightly stronger, albeit statistically 
non-significant.  
We further conducted stratified analysis to examine whether the association between plasma 
fetuin-A and colorectal cancer risk differed by age, body fatness (BMI and waist circumference), 
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alcohol consumption, and concentrations of HbA1c and C-peptide. No significant association 
between fetuin-A and risk of colorectal cancer was observed in any strata, and there was no 
indication of interaction by any of these factors (supplemental table 2). 
In the subset of participants with available data on fetuin-A, C-peptide, HbA1c and soluble leptin 
receptor (465 cases and 465 matched controls), the risk estimate for the association between 
plasma fetuin-A and risk of colorectal cancer was the same as in the full sample, but the 
confidence interval was wider (OR per 40 µg/mL in multivariable model including body fatness 
1.11, 95% CI 0.94, 1.32) and therefore the association lost statistical significance. Adding 
metabolic biomarkers to the model did not alter the association in the subset: OR (95% CI) per 40 
µg/mL fetuin-A increment was 1.11 (0.94, 1.32) after adding log-transformed C-peptide, 1.11 
(0.94-1.31) after adding log-transformed HbA1c, 1.11 (0.94, 1.31) after adding a factor score 
combining C-peptide and HbA1c, and 1.13 (0.96, 1.34) after adding log-transformed 
concentration of soluble leptin receptor. 
Among control participants with available data on both plasma fetuin-A and AHSG SNPs 
(n=483), 4 of the 5 selected tagging SNPs in the AHSG gene were associated with plasma 
concentrations of fetuin-A (Figure 2). The weighted AHSG-score was associated with 30.4 µg/ml 
(95% CI 25.7; 35.2) higher plasma fetuin-A per score unit, which explained 21% of the inter-
individual variation in plasma fetuin-A (F-value=287). Most potentially confounding or 
mediating lifestyle, dietary and metabolic factors did not differ substantially across AHSG-score 
tertiles (Supplemental table 3). However, higher AHSG-score appeared to be negatively 
associated with age at blood collection (p-trend 0.03) and soluble leptin-receptor (p-trend 0.02), 
but was positively associated with BMI (p-trend 0.01). When using the AHSG-score as 
instrumental variable in a Mendelian randomization analysis, no positive association between 
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genetically raised fetuin-A and risk of colorectal cancer was observed (OR per 40 µg/mL 
genetically determined higher fetuin-A 0.98, 95% CI 0.73, 1.33), arguing against a causal 
association. The estimate was not altered substantially after adjustment for matching factors 
including age (OR 0.99, 95% CI 0.73, 1.33), or additional adjustment for BMI (OR 0.94, 95% CI 
0.69, 1.28). Genetically raised fetuin-A was unrelated to risk of colorectal cancer in men (OR 
1.04, 95% CI 0.68, 1.60) and women (OR 0.93, 95% CI 0.93, 1.42). Mendelian Randomization 
estimates for genetically raised fetuin-A were 1.15 (95% CI 0.81, 1.63) for risk of colon cancer 
and 0.68 (95% CI 0.37, 1.24) for risk of rectal cancer. It should be noted that the sample size for 
these subgroup analyses was limited.  
Discussion 
In this prospective study, we found a modest positive association between plasma fetuin-A 
concentrations and risk of colorectal cancer, adjusting for a variety of potentially confounding 
factors. However, significant associations were only observed when fetuin-A was modeled as a 
continuous variable, and not when comparing quintiles of fetuin-A concentrations. Furthermore, 
associations were restricted to male participants, while no statistically significant associations 
were observed in women. The observed associations between fetuin-A and risk of colorectal 
cancer were only slightly attenuated after adjustment for body fatness and were not substantially 
influenced by additional adjustment (in a subset) for C-peptide or HbA1c. In contrast to these 
observations, genetically raised fetuin-A concentrations were not associated with a higher risk of 
colorectal cancer in the Mendelian Randomization analysis, arguing against the hypothesis that 
plasma fetuin-A concentrations play a causal role in colorectal carcinogenesis.  
To our knowledge this is the first prospective study to examine circulating fetuin-A 
concentrations in relation to risk of colorectal cancer. Biological mechanisms for a positive 
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association between fetuin-A and risk of colorectal cancer are conceivable through fetuin-A’s  
impact on obesity
8, 33, 34
 and insulin resistance
1, 5-7
, since markers of obesity, insulin resistance  
and hyperinsulinemia have been associated with higher risk of colorectal cancer in a number of  
prospective studies 
14, 35
, including findings from the EPIC cohort 
17, 18, 36
. There is also some  
evidence showing that fetuin-A mediates the adhesion of tumor cells, which is an important step  
in tumor growth and motility as well as development of metastases 
37
.   While we found a  
positive association between measured fetuin-A and risk of colorectal cancer , the Mendelian  
Randomization analysis, 
19, 29, 31
, argues against a causal effect of fetuin-A on colorectal cancer  
risk: Genetically raised fetuin-A was not associated with risk of colorectal cancer. One possible  
explanation for this discrepancy is that pre-clinical colorectal cancer may have resulted in  
elevated fetuin-A concentrations. In fact, we found some evidence for such reverse causality in  
the observational analysis: the linear association between measured fetuin-A and risk of  
colorectal cancer was slightly attenuated after excluding the first two years of follow-up.  
However, the attenuation was small and may also be due to chance. It is currently unclear how  
preclinical colorectal cancer may result in an upregulation of fetuin-A expression, but in a recent  
proteomics study, a fetuin-A precursor was found to be up-regulated in post-diagnostic plasma of  
colorectal cancer patients as compared to healthy volunteers and authors suggested this precursor  
as potential diagnosis marker for colorectal cancer 
38
. In contrast, in a small cross-sectional study  
comparing fetuin-A concentrations between 32 colorectal cancer patients and 30 control  
participants no differences were observed 
39
.   
Within the limits of our study we tried to control for potential confounding as completely as  
possible in our analysis. However, an uncontrolled or insufficiently controlled environmental or  
lifestyle factor associated with both fetuin-A and colorectal cancer may have influenced our  
findings on plasma fetuin-A concentrations and risk of colorectal cancer. Therefore, besides  
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reverse causation, the observed significant association of measured circulating fetuin-A and  
colorectal cancer may also be explained by residual confounding. This is in contrast to the null  
association found in our Mendelian Randomization analysis, which circumvents reverse  
causation and uncontrolled confounding
18, 28, 30
, thus suggesting that fetuin-A has no causal role  
for colorectal cancer.  
 The limited sample size for the Mendelian Randomization analysis is a limitation of our study.  
Instrumental variable estimates can be biased when both the variance explained by the  
instruments and the sample size are small 
29
. However, the selected polymorphisms in the AHSG  
gene were strong predictors of fetuin-A concentrations, explaining a good proportion of inter- 
individual variation. Nevertheless, as reflected by the wide confidence interval of the  
instrumental variable estimate, our study had limited statistical power to detect small effects, and  
we cannot exclude that a modest association between genetically raised fetuin-A and colorectal  
cancer risk would have been detected in a Mendelian Randomization study with substantially  
larger sample size. Of note, in a previous Mendelian Randomization study in EPIC with a similar  
sample size, a significant association between genetically raised CRP and risk of colorectal  
cancer was observed, even though the instrument strength of the CRP-score was weaker than of  
the here applied AHSG-score 
40
. It should also be noted that the AHSG-score was not completely  
independent of potentially confounding factors. Both BMI and soluble leptin-receptor differed  
significantly by tertiles of the AHSG-score. This finding, however, is consistent with  studies  
showing that certain AHSG genotypes are more common in obese than in lean people 
33
; With  
respect to the analysis of the association between measured circulating fetuin-A and risk of  
colorectal cancer, random measurement error may have attenuated observed associations. It also  
is a limitation of our study that fetuin-A was measured only once at baseline and thus may not  
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necessarily represent long-term values. Furthermore, we cannot exclude that storage time  
influenced fetuin-A values.    
Strengths of our study include the prospective design, the ability to adjust for a variety of  
potentially confounding factors including metabolic biomarkers as well as the ability to  
investigate potential causality in a Mendelian Randomization approach using multiple AHSG  
genetic variants which were strongly associated with fetuin-A concentrations.   
In conclusion, the findings of our study suggest that high fetuin-A concentrations are associated  
with a modest higher risk of colorectal cancer, but that fetuin-A may not be causally related to  
colorectal cancer development. Both, the basic association between circulating fetuin-A and risk  
of colorectal cancer as well as the lack of association between genetically raised fetuin-A and  
colorectal cancer risk warrant confirmation by further studies.  
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Table 2. Association between plasma fetuin-A concentrations and risk of colorectal cancer  
            First 2 years of follow-up excluded 
Fetuin-A Ca/Co OR
1
 (95% CI) OR
2
  (95% CI) Ca/Co OR
2
  (95% CI) 
Colorectal cancer, overall 
 
Quintile 1 268/271 1.00 Reference 1.00 Reference 221/210 1.00 Reference 
Quintile 2 254/281 0.93 (0.73-1.19) 0.94 (0.73-1.21) 211/235 0.89 (0.67-1.17) 
Quintile 3 274/283 0.98 (0.76-1.25) 0.96 (0.75-1.24) 226/244 0.86 (0.65-1.14) 
Quintile 4 266/269 1.03 (0.78-1.34) 1.01 (0.77-1.33) 228/230 0.96 (0.71-1.30) 
Quintile 5 305/263 1.27 (0.95-1.70) 1.22 (0.91-1.63) 264/231 1.11 (0.80-1.53) 
p-trend   0.08  0.16  0.43 
per 40 µg/ml (1 SD) 1.13 (1.02-1.24) 1.11 (1.01-1.22) 1.09 (0.98-1.21) 
Colorectal cancer, men 
  
Quintile 1 131/134 1.00 Reference 1.00 Reference 101/103 1.00 Reference 
Quintile 2 124/123 1.12 (0.76-1.63) 1.13 (0.77-1.65) 102/97 1.19 (0.77-1.84) 
Quintile 3 116/148 0.82 (0.56-1.20) 0.81 (0.55-1.20) 90/126 0.75 (0.48-1.16) 
Quintile 4 124/129 1.02 (0.68-1.53) 1.01 (0.67-1.51) 105/109 1.06 (0.68-1.68) 
Quintile 5 162/123 1.62 (1.04-2.51) 1.55 (1.00-2.41) 141/104 1.66 (1.01-2.72) 
p-trend   0.06  0.09  0.08 
per 40 µg/ml (1 SD) 1.21 (1.05-1.39) 1.18 (1.03-1.37) 1.21 (1.03-1.42) 
Colorectal cancer, women 
  
Quintile 1 137/137 1.00 Reference 1.00 Reference 120/107 1.00 Reference 
Quintile 2 130/158 0.79 (0.56-1.12) 0.80 (0.57-1.13) 109/138 0.68 (0.47-1.00) 
Quintile 3 158/135 1.11 (0.79-1.58) 1.10 (0.77-1.56) 136/118 0.94 (0.64-1.38) 
Quintile 4 142/140 1.00 (0.69-1.46) 0.99 (0.68-1.44) 123/121 0.86 (0.56-1.30) 
Quintile 5 143/140 1.02 (0.68-1.53) 0.99 (0.66-1.49) 123/127 0.81 (0.51-1.29) 
p-trend   0.58  0.71  0.72 
per 40 µg/ml (1 SD) 1.06 (0.93-1.22) 1.05 (0.92-1.21) 1.00 (0.86-1.17) 
p for heterogeneity by sex
 3
 0.21   0.24     0.18 
Quintile cut-offs were 195.2, 216.3, 235.8 and 259.0. 
1
Conditioned on matching factors and adjusted for education (no degree/primary, technical/professional, secondary, university, not 
specified), physical activity (sex-specific quartiles), smoking status (never, past, current, unknown), nondrinker, alcohol intake 
(continuous, g/day), energy intake (continuous, kcal/day), fiber intake, fruit and vegetable intake, red meat intake, processed meat intake, 
fish intake (continuous, g/day)   
2
 additionally adjusted for body mass index and waist circumference residuals 
3 
p-value for heterogeneity by sex derived from inverse variance method (Q-statistic for heterogeneity) 
Ca/Co, Number of cases/number of controls; OR, Odds ratio 
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Table 3. Association betweeen plasma fetuin-A concentrations and risk of colon and rectal cancer 
             First 2 years of follow-up excluded 
Fetuin-A Ca/Co OR
1
 (95% CI) OR
2
  (95% CI) Ca/Co OR
2
  (95% CI) 
       
Colon cancer   
Quintile 1 177/181 1.00 Reference 1.00 Reference 149/139 1.00 Reference 
Quintile 2 158/183 0.88 (0.65-1.20) 0.90 (0.66-1.23) 137/155 0.83 (0.59-1.17) 
Quintile 3 173/181 0.95 (0.69-1.31) 0.94 (0.68-1.29) 144/156 0.82 (0.58-1.17) 
Quintile 4 176/170 1.05 (0.75-1.48) 1.05 (0.75-1.48) 152/150 0.91 (0.63-1.33) 
Quintile 5 188/161 1.28 (0.90-1.82) 1.23 (0.86-1.75) 159/144 1.00 (0.67-1.49) 
p-trend   0.11  0.19  0.85 
per 40 µg/ml (1 SD) 1.13 (1.00-1.27) 1.11 (0.99-1.25) 1.04 (0.92-1.19) 
Rectal cancer   
Quintile 1 91/90 1.00 Reference 1.00 Reference 72/71 1.00 Reference 
Quintile 2 96/98 1.04 (0.67-1.62) 1.04 (0.67-1.61) 74/80 1.02 (0.62-1.68) 
Quintile 3 101/102 0.98 (0.63-1.52) 0.96 (0.62-1.49) 82/88 0.94 (0.58-1.52) 
Quintile 4 90/99 0.96 (0.60-1.53) 0.93 (0.58-1.49) 76/80 1.05 (0.62-1.77) 
Quintile 5 117/102 1.26 (0.75-2.13) 1.21 (0.71-2.05) 105/87 1.46 (0.82-2.61) 
p-trend   0.49  0.61  0.23 
per 40 µg/ml (1 SD) 1.12 (0.94-1.32) 1.10 (0.92-1.30) 1.18 (0.98-1.43) 
p for heterogeneity by location
3
 0.08   0.89     0.57 
Quintile cut-offs were 195.2, 216.3, 235.8 and 259.0. 
1 
Conditioned on matching factors and adjusted for education (no degree/primary, technical/professional, secondary, university, not 
specified), physical activity (sex-specific quartiles), smoking status (never, past, current, unknown), nondrinker, alcohol intake 
(continuous, g/day), energy intake (continuous, kcal/day), fiber intake, fruit and vegetable intake, red meat intake, processed meat intake, 
fish intake (continuous, g/day)   
2
 additionally adjusted for body mass index and waist circumference residuals 
3
 p for heterogeneity by location based on competing risk test 
Ca/Co, Number of cases/number of controls; OR, Odds ratio 
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Figure Legends 
 
 
 
 
 
Figure 1. Association between AHSG genetic variation (individual AHSG SNPs and combined 
score) and fetuin-A concentration among controls with available data on both fetuin-A and AHSG 
genotypes (n=483) 
 
Bars indicate 95% confidence intervals. P-values for trend were <0.0001 except for rs6787344 (p 
for trend 0.08). Models were unadjusted. 
* Incorporated in AHSG-score (weighted allele-score, created by summing each genotype 
multiplied by its estimated coefficient from the linear regression, divided by the sum of weights). 
† 
Continuous estimate (95% CI) for mean difference in fetuin-A (µg/mL)  
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